Day One Biopharmaceuticals, Inc. (DAWN)

Day One Biopharmaceuticals' stock (DAWN) has experienced significant movements, including a substantial increase over the last six months. In March 2026, Day One Biopharmaceuticals agreed to a $2.5 billion buyout offer from Servier. Several research firms have downgraded Day One Biopharmaceuticals' stock. In February 2026, Day One reported its Fourth Quarter and Full Year 2025 financial results, which included a narrower net loss and an 82% jump in OJEMDA sales. The company's Q3 2025 earnings in November 2025 showed an EPS of -$0.19 and revenue of $39.8M.

Information regarding the specific demand seasonality for Day One Biopharmaceuticals' products and services is not readily available.

Day One Biopharmaceuticals, Inc. (DAWN) is focused on developing and commercializing targeted therapies for life-threatening diseases, particularly pediatric cancer. The company's pipeline includes Tovorafenib (OJEMDA™), DAY301, and Emi-Le (emiltatug ledadotin).

Day One Biopharmaceuticals, Inc. is headquartered in Brisbane, California, United States, with a focus on the U.S. for its operations and clinical development. The company is incorporated in the State of Delaware.

Day One Biopharmaceuticals' brand reputation has a consensus rating of "Hold" from ten ratings firms. Events affecting the company's reputation include the stock price increase, the buyout offer from Servier, analyst downgrades, the acquisition of Mersana Therapeutics, and financial results.

Day One Biopharmaceuticals, Inc. has a significant portion of its stock held by institutional shareholders and insiders. Major institutional owners include BlackRock, Inc., Atlas Venture Life Science Advisors, LLC, and Vanguard Group Inc. Major individual/insider owners include Ai Day1 LLC, Papanek Julie Grant, and Jeremy Bender.